Effect of long-term treatment with low-dose mifepristone on the endometrium

被引:78
作者
Baird, DT
Brown, A
Critchley, HOD
Williams, AR
Lin, S
Cheng, L
机构
[1] Univ Edinburgh, Ctr Reprod Biol, Contracept Dev Network, Acad Ctr, Edinburgh EH16 4SB, Midlothian, Scotland
[2] Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland
[3] Shanghai Inst Family Planning Tech Instruct, Shanghai, Peoples R China
基金
英国医学研究理事会;
关键词
antigestogen; antiproliferation; contraception; mifepristone;
D O I
10.1093/humrep/deg022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Mifepristone in low daily doses has contraceptive potential by inhibiting ovulation and menstruation. Because follicular development is maintained, the endometrium is exposed to estrogen for prolonged periods unopposed by progesterone. METHODS: Endometrial biopsies were collected from 90 women in Edinburgh and Shanghai before (late proliferative) and 60 and 120 days after taking 2 or 5 mg mifepristone per day for 120 days. RESULTS: Ovulation and menstruation were inhibited in >90% of cycles and estrogen production was similar to that observed during the follicular phase of the control cycle. By 120 days, endometrial thickness increased significantly in women in Edinburgh but decreased in Shanghai. Endometrial histology showed inactive proliferative or cystic changes with dense stroma. There was a significant decrease in markers of proliferation, i.e. mitotic index and Ki67 staining. There were no pregnancies in a total of 200 women-months in 50 sexually active women who used no other method of contraception. CONCLUSIONS: We confirm that ovulation and menstruation were suppressed in the majority of cycles and there was asynchrony between ovarian activity and endometrial histology, which showed no signs of hyperplasia or atypia. These preliminary data suggest that daily low-dose mifepristone is potentially a safe estrogen-free contraceptive pill which has the added health benefit of amenorrhoea.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 30 条
[1]  
ALDERCREUTZ H, 1994, JNCI-J NATL CANCER I, V86, P1076
[2]   Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study .3. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterones [J].
Anderson, RA ;
Wallace, AM ;
Wu, FCW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :902-908
[3]   Science, medicine, and the future - Contraception [J].
Baird, DT ;
Glasier, AF .
BRITISH MEDICAL JOURNAL, 1999, 319 (7215) :969-972
[4]  
BAIRD DT, 2001, REPROD FERT DEVELOP, V13, P1
[5]   Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor [J].
Brenner, RM ;
Slayden, OD ;
Critchley, HOD .
REPRODUCTION, 2002, 124 (02) :167-172
[6]   Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days [J].
Brown, A ;
Cheng, LN ;
Lin, SQ ;
Baird, DT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :63-70
[7]  
Cameron ST, 1996, HUM REPROD, V11, P2518
[8]   EFFECT OF DAILY LOW-DOSE MIFEPRISTONE ON THE OVARIAN CYCLE AND ON DYNAMICS OF FOLLICLE GROWTH [J].
CAMERON, ST ;
THONG, KJ ;
BAIRD, DT .
CLINICAL ENDOCRINOLOGY, 1995, 43 (04) :407-414
[9]   Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium [J].
Chwalisz, K ;
Brenner, RM ;
Fuhrmann, UU ;
Hess-Stumpp, H ;
Elger, W .
STEROIDS, 2000, 65 (10-11) :741-751
[10]   Effects of long-term low-dose mifepristone on reproductive function in women [J].
Croxatto, HB ;
Kovács, L ;
Massai, R ;
Resch, BA ;
Fuentealba, B ;
Salvatierra, AM ;
Croxatto, HD ;
Zalányi, S ;
Viski, S ;
Krenacs, L .
HUMAN REPRODUCTION, 1998, 13 (04) :793-798